Although it might be frustrating for those competing against each other, healthy competition often leads to beneficial results on the whole. This is the case for the EGFR-mutated non-small-cell lung cancer treatments, Yuhan Corp’s Leclaza (lasertinib) and AstraZeneca’s ‘Tagrisso (osimiertinib).’

Both drugs are third-generation tyrosine kinase inhibitors (TKIs) targeting EGFR-mutated non-small cell lung cancer, and are currently used as first- and second-line treatment in the field.

The two are same-generation drugs that own the same indications. Both have proven their effect in terms of brain metastasis, efficacy, and safety, which are important factors in treating cancer patients. Y